A new CEO will equal a "different, more transparent" Pharmac, according to the board chair of the drug-buying agency's as patient advocates warn that a fresh perspective is needed to shed the ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Associate Health Minister David Seymour has today acknowledged the resignation of Pharmac Chief Executive Dr. Sarah Fitt and expressed gratitude for her dedicated service to New Zealand’s healthcare ...

The Board of Pharmac wishes to announce that its Chief Executive for the last 7 years, Sarah Fitt, has resigned effective from 30 May 2025. The Board and Pharmac are appreciative of all of Sarah's ...

The chief executive of New Zealand medicines agency Pharmac for the past seven years, Sarah Fitt, has resigned. The agency’s board announced today, February 28, that Fitt will leave the role on May 30 ...

Reuters FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...